Analysts Set InVitae Corp (NASDAQ:NVTA) Target Price at $15.00

Shares of InVitae Corp (NASDAQ:NVTA) have received a consensus rating of “Hold” from the six analysts that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $15.00.

NVTA has been the topic of several recent analyst reports. Benchmark Co. reaffirmed a “buy” rating and set a $16.00 price target (up previously from $11.00) on shares of InVitae Corp in a research report on Monday, April 3rd. ValuEngine cut InVitae Corp from a “sell” rating to a “strong sell” rating in a report on Tuesday, May 23rd.

Hedge funds have recently modified their holdings of the company. Perceptive Advisors LLC bought a new stake in shares of InVitae Corp during the fourth quarter valued at approximately $3,970,000. Renaissance Technologies LLC acquired a new stake in shares of InVitae Corp during the fourth quarter worth approximately $879,000. Vanguard Group Inc. increased its stake in shares of InVitae Corp by 9.8% in the first quarter. Vanguard Group Inc. now owns 1,206,266 shares of the medical research company’s stock worth $13,341,000 after buying an additional 107,775 shares during the last quarter. Teton Advisors Inc. acquired a new stake in shares of InVitae Corp during the first quarter worth approximately $564,000. Finally, TIAA CREF Investment Management LLC increased its stake in shares of InVitae Corp by 32.8% in the first quarter. TIAA CREF Investment Management LLC now owns 121,549 shares of the medical research company’s stock worth $1,344,000 after buying an additional 30,039 shares during the last quarter.

WARNING: This piece of content was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/07/12/brokerages-set-invitae-corp-nvta-price-target-at-15-00-updated-updated.html.

Shares of InVitae Corp (NASDAQ:NVTA) traded up 2.582% on Monday, hitting $9.735. 193,327 shares of the stock traded hands. The firm’s 50-day moving average is $9.21 and its 200 day moving average is $9.50. The firm’s market cap is $411.93 million. InVitae Corp has a 12-month low of $5.76 and a 12-month high of $11.88.

InVitae Corp (NASDAQ:NVTA) last issued its earnings results on Tuesday, May 9th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.04. The firm had revenue of $10.34 million for the quarter, compared to analysts’ expectations of $10.90 million. InVitae Corp had a negative return on equity of 119.10% and a negative net margin of 260.48%. The company’s revenue was up 161.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.80) earnings per share. Equities research analysts forecast that InVitae Corp will post ($2.37) EPS for the current fiscal year.

InVitae Corp Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply